2017
DOI: 10.1523/jneurosci.0214-17.2017
|View full text |Cite
|
Sign up to set email alerts
|

Perspectives on Treatment of Alzheimer's Disease: A Closer Look into EphB2 Depletion

Abstract: Editor's Note: These short reviews of recent JNeurosci articles, written exclusively by students or postdoctoral fellows, summarize the important findings of the paper and provide additional insight and commentary. If the authors of the highlighted article have written a response to the Journal Club, the response can be found by viewing the Journal Club at www.jneurosci.org. For more information on the format, review process, and purpose of Journal Club articles, please see http://jneurosci.org/content/ prepar… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
6
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(6 citation statements)
references
References 14 publications
0
6
0
Order By: Relevance
“…Together with the accumulating evidences, EphB2 mediates the excitatory synaptogenesis during development and coordinates synaptic plasticity by controlling the localization and function of glutamate receptors 27,59 . Previous studies also show that EphB2 signal is related to anxiety disorders 62 , autism 63,64 , and cognitive dysfunction 41,65 . Our study expands the understanding of the (see figure on previous page) Fig.…”
Section: Discussionmentioning
confidence: 79%
“…Together with the accumulating evidences, EphB2 mediates the excitatory synaptogenesis during development and coordinates synaptic plasticity by controlling the localization and function of glutamate receptors 27,59 . Previous studies also show that EphB2 signal is related to anxiety disorders 62 , autism 63,64 , and cognitive dysfunction 41,65 . Our study expands the understanding of the (see figure on previous page) Fig.…”
Section: Discussionmentioning
confidence: 79%
“…We have focused our efforts on exploring whether GSMs affect the processing of E‐cadherin, ephrin type B receptor 2 (EphB2) and ephrin type A receptor 4 (EphA4), which are known to mediate important cell signalling and may have been associated with severe side effects in response to γ‐secretase inhibitor trials (i.e., semagacestat and avagacestat). 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 We find that GSMs, in contrast to their effect on APP processing, do not affect the processing of E‐cadherin, EphB2 and EphA4 to a large extent. Rather, our data suggest that GSMs are selective for γ‐secretase–mediated APP processing and support the further development of GSMs as a tolerable and effective anti‐amyloidogenic treatment for the treatment of AD.…”
Section: Introductionmentioning
confidence: 68%
“…A key objective of the current study was to study how GSM as a class of anti‐amyloid agents affects γ‐secretase–catalysed reactions in a broader context beyond APP and Notch processing. We chose to study EphB2, EphA4 and E‐cadherin processing based on their documented function and important signalling in different physiological and pathophysiological contexts, such as synaptic plasticity, memory formation, cell proliferation and cancer, 27 , 28 , 29 , 30 , 31 , 32 , 33 which have been implicated in the adverse events associated with γ‐secretase inhibitor trials in AD patients. 13 , 14 …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Moreover, it has been shown that Alzheimer disease-linked amyloid-β oligomers bind to the fibronectin domains of EphB2 and trigger receptor degradation in the proteasome [ 14 ]. Thus, augmenting EphB2 activity could have beneficial effects in Alzheimer disease by reversing long-term potentiation impairments [ 15 ]. Therapeutic strategies targeting amyloid-β oligomers were recently reviewed in [ 16 ].…”
Section: Introductionmentioning
confidence: 99%